Selected research
Industry Research
Galectin 3 Industry Research Report 2026
Market perspective
The global Galectin 3 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Galectin 3 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Galectin 3 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Galectin 3 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Galectin 3 include MandalMed Inc, iTeos Therapeutics SA, GlycoMimetics Inc, Galectin Therapeutics Inc, Bristol-Myers Squibb Company and Angion Biomedica Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Galectin 3 market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Galectin 3 Market by Company
MandalMed Inc
iTeos Therapeutics SA
GlycoMimetics Inc
Galectin Therapeutics Inc
Bristol-Myers Squibb Company
Angion Biomedica Corp
Galectin 3 Segment by Type
KTI
GRMD-03
GAL-300
ANG-4021
Others
Galectin 3 Segment by Application
Metastatic Melanoma
Portal Hypertension
Liver Cirrhosis
Others
Galectin 3 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Galectin 3 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Galectin 3 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Galectin 3.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Galectin 3 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Galectin 3 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Galectin 3 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- KTI
- GRMD-03
- GAL-300
- ANG-4021
- Others
Applications
- Metastatic Melanoma
- Portal Hypertension
- Liver Cirrhosis
- Others
Companies covered
- MandalMed Inc
- iTeos Therapeutics SA
- GlycoMimetics Inc
- Galectin Therapeutics Inc
- Bristol-Myers Squibb Company
- Angion Biomedica Corp
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Galectin 3 Market Size (2021-2032)
- 2.2.2 Global Galectin 3 Sales (2021-2032)
- 2.2.3 Global Galectin 3 Market Average Price (2021-2032)
- 2.3 Galectin 3 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 KTI
- 2.3.3 GRMD-03
- 2.3.4 GAL-300
- 2.3.5 ANG-4021
- 2.3.6 Others
- 2.4 Galectin 3 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Metastatic Melanoma
- 2.4.3 Portal Hypertension
- 2.4.4 Liver Cirrhosis
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Galectin 3 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Galectin 3 Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Galectin 3 Revenue of Manufacturers (2021-2026)
- 3.4 Global Galectin 3 Average Price by Manufacturers (2021-2026)
- 3.5 Global Galectin 3 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Galectin 3, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Galectin 3, Product Type & Application
- 3.8 Global Manufacturers of Galectin 3, Established Date
- 3.9 Global Galectin 3 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 MandalMed Inc
- 4.1.1 MandalMed Inc Company Information
- 4.1.2 MandalMed Inc Business Overview
- 4.1.3 MandalMed Inc Galectin 3 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 MandalMed Inc Galectin 3 Product Portfolio
- 4.1.5 MandalMed Inc Recent Developments
- 4.2 iTeos Therapeutics SA
- 4.2.1 iTeos Therapeutics SA Company Information
- 4.2.2 iTeos Therapeutics SA Business Overview
- 4.2.3 iTeos Therapeutics SA Galectin 3 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 iTeos Therapeutics SA Galectin 3 Product Portfolio
- 4.2.5 iTeos Therapeutics SA Recent Developments
- 4.3 GlycoMimetics Inc
- 4.3.1 GlycoMimetics Inc Company Information
- 4.3.2 GlycoMimetics Inc Business Overview
- 4.3.3 GlycoMimetics Inc Galectin 3 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlycoMimetics Inc Galectin 3 Product Portfolio
- 4.3.5 GlycoMimetics Inc Recent Developments
- 4.4 Galectin Therapeutics Inc
- 4.4.1 Galectin Therapeutics Inc Company Information
- 4.4.2 Galectin Therapeutics Inc Business Overview
- 4.4.3 Galectin Therapeutics Inc Galectin 3 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Galectin Therapeutics Inc Galectin 3 Product Portfolio
- 4.4.5 Galectin Therapeutics Inc Recent Developments
- 4.5 Bristol-Myers Squibb Company
- 4.5.1 Bristol-Myers Squibb Company Company Information
- 4.5.2 Bristol-Myers Squibb Company Business Overview
- 4.5.3 Bristol-Myers Squibb Company Galectin 3 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bristol-Myers Squibb Company Galectin 3 Product Portfolio
- 4.5.5 Bristol-Myers Squibb Company Recent Developments
- 4.6 Angion Biomedica Corp
- 4.6.1 Angion Biomedica Corp Company Information
- 4.6.2 Angion Biomedica Corp Business Overview
- 4.6.3 Angion Biomedica Corp Galectin 3 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Angion Biomedica Corp Galectin 3 Product Portfolio
- 4.6.5 Angion Biomedica Corp Recent Developments
5 Global Galectin 3 Market Scenario by Region
- 5.1 Global Galectin 3 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Galectin 3 Sales by Region: 2021-2032
- 5.2.1 Global Galectin 3 Sales by Region: 2021-2026
- 5.2.2 Global Galectin 3 Sales by Region: 2027-2032
- 5.3 Global Galectin 3 Revenue by Region: 2021-2032
- 5.3.1 Global Galectin 3 Revenue by Region: 2021-2026
- 5.3.2 Global Galectin 3 Revenue by Region: 2027-2032
- 5.4 North America Galectin 3 Market Facts & Figures by Country
- 5.4.1 North America Galectin 3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Galectin 3 Sales by Country (2021-2032)
- 5.4.3 North America Galectin 3 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Galectin 3 Market Facts & Figures by Country
- 5.5.1 Europe Galectin 3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Galectin 3 Sales by Country (2021-2032)
- 5.5.3 Europe Galectin 3 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Galectin 3 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Galectin 3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Galectin 3 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Galectin 3 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Galectin 3 Market Facts & Figures by Country
- 5.7.1 South America Galectin 3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Galectin 3 Sales by Country (2021-2032)
- 5.7.3 South America Galectin 3 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Galectin 3 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Galectin 3 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Galectin 3 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Galectin 3 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Galectin 3 Sales by Type (2021-2032)
- 6.1.1 Global Galectin 3 Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Galectin 3 Sales Market Share by Type (2021-2032)
- 6.2 Global Galectin 3 Revenue by Type (2021-2032)
- 6.2.1 Global Galectin 3 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Galectin 3 Revenue Market Share by Type (2021-2032)
- 6.3 Global Galectin 3 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Galectin 3 Sales by Application (2021-2032)
- 7.1.1 Global Galectin 3 Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Galectin 3 Sales Market Share by Application (2021-2032)
- 7.2 Global Galectin 3 Revenue by Application (2021-2032)
- 7.2.1 Global Galectin 3 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Galectin 3 Revenue Market Share by Application (2021-2032)
- 7.3 Global Galectin 3 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Galectin 3 Value Chain Analysis
- 8.1.1 Galectin 3 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Galectin 3 Production Mode & Process
- 8.2 Galectin 3 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Galectin 3 Distributors
- 8.2.3 Galectin 3 Customers
9 Global Galectin 3 Analyzing Market Dynamics
- 9.1 Galectin 3 Industry Trends
- 9.2 Galectin 3 Industry Drivers
- 9.3 Galectin 3 Industry Opportunities and Challenges
- 9.4 Galectin 3 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst